TUNE-401 larger Phase 2 starts
After its May 2026 Phase 1b/2a HBV update, Tune said it was advancing a larger Phase 2 study. TUNE-401 uses liver-directed epigenetic silencing of HBV transcriptional reservoirs.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- A Phase 1b/2a study already exists. Distinguish the larger follow-on protocol and verify whether first dosing has occurred.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Company target: as early as late 2026; exact day unconfirmed
Company context
Company-authored LinkedIn About explicitly states Type: Privately Held and links tunetx.com. Opened and checked October 31, 2026. This is an undated company self-report, not independent registry proof; it does not establish program outcome status.
Potential outcome market
Will the first participant be dosed in the new larger Phase 2 TUNE-401 study by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.